UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER, INC. and SAMSUNG BIOEPIS CO., LTD.,¹

Petitioner,

v.

GENENTECH, INC., Patent Owner.

Case IPR2017-01489 Patent 6,407,213

PETITIONERS' UPDATED EXHIBIT LIST

¹ Samsung Bioepis Co. Ltd.'s IPR2017-02140 has been joined with this proceeding.

(IPR2017-02140, Paper 40.)

DOCKE'

Δ

IPR2017-01489 Petitioners' Updated Exhibit List

PETITIONER'S EXHIBIT LIST		
Exhibit No.	Description	
1501	U.S. Patent No. 6,407,213, <i>Method for making humanized antibodies</i> (filed July 17, 1993) (issued June 18, 2002)	
1502 Vols. 1–10	File History for U.S. Patent No. 6,407,213	
1503	Declaration of Dr. Foote in Support of Petition for <i>Inter Partes</i> Review of Patent No. 6,407,213	
1503A	Curriculum Vitae of Dr. Foote	
1503B	Materials Reviewed by Dr. Foote	
1503C-Q	Exhibits C–Q of Dr. Foote's Declaration	
1504	Declaration of Mr. Buss in Support of Petition for <i>Inter Partes</i> Review of Patent No. 6,407,213	
1504A	Curriculum Vitae of Mr. Buss	
1504B	Materials Reviewed by Mr. Buss	
1505	Reserved	
1506	Reserved	
1507	Reserved	
1508	Reserved	
1509	Reserved	
1510	Reserved	
1511	Reserved	
1512	Reserved	
1513	Reserved	
1514	Reserved	
1515	Reserved	
1516	Reserved	
1517	Reserved	
1518	Reserved	
1519	Reserved	
1520	Reserved	

IPR2017-01489 Petitioners' Updated Exhibit List

PETITIONER'S EXHIBIT LIST		
Exhibit No.	Description	
1521	Hudziak et al., p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor, 9(3) MOLECULAR CELLULAR BIOLOLGY 1165–72 (1989) ("Hudziak")	
1522	Köhler et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, 256(5517) NATURE 495–97 (1975)	
1523	Prabakaran, <i>The Quest for a Magic Bullet</i> , 349(6246) SCIENCE 389 (2015)	
1524	Marks, <i>The Story of Cesar Milstein and Monoclonal Antibodies: A Healthcare Revolution in the Making</i> , http://www.whatisbiotechnology.org/exhibitions/milstein (last accessed March 23, 2017)	
1525	Cosimi et al., Treatment of Acute Renal Allograft Rejection with OKT3 Monoclonal Antibody, 32(6) TRANSPLANTATION 535–39 (1981) ("Cosimi '81")	
1526	Ortho Multicenter Transplant Study Group, A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadveric Renal Transplants, 313(6) NEW ENG. J. MED. 337–42 (1985) ("OMTSG '85")	
1527	Jaffers et al., Monoclonal Antibody Therapy: Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression, 41(5) TRANSPLANTATION 572–78 (1986) ("Jaffers '86")	
1528	Sears et al., Phase-I Clinical Trial of Monoclonal Antibody in Treatment of Gastrointestinal Tumours, 1 LANCET 762–65 (1982)	
1529	Sikora, <i>Monoclonal Antibodies in Oncology</i> , 35(4) J. CLINICAL PATHOLOGY 369–75 (1982)	
1530	<i>Protein Data Bank - Chronology</i> , National Science Foundation, https://www.nsf.gov/news/news_summ.jsp?cntn_id=100689 (last accessed April 12, 2017)	

IPR2017-01489 Petitioners' Updated Exhibit List

PETITIONER'S EXHIBIT LIST		
Exhibit No.	Description	
1531	Morrison et al., Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains, 81(21) PROC. NAT'L ACAD. SCI. USA 6851–55 (1984) ("Morrison '84")	
1532	Liu et al., Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis of Cancer Cells, 84(10) PROC. NAT'L ACAD. SCI. USA 3439–43 (1987) ("Liu '87")	
1533	Jones et al., Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse, 321(6069) NATURE 522–25 (1986) ("Jones '86")	
1534	Queen et al., A Humanized Antibody That Binds to the Interleukin 2 Receptor, 86(24) PROC. NAT'L ACAD. SCI. USA 10029–33 (1989) ("Queen 1989")	
1535	Kirkman et al., Early Experience with Anti-Tac in Clinical Renal Transplantation, 21(1) TRANSPLANTATION PROC. 1766–68 (1989) ("Kirkman '89")	
1536	Waldmann et al., The Interleukin-2 Receptor: A Target for Monoclonal Antibody Treatment of Human T-Cell Lymphotrophic Virus I-Induced Adult T-Cell Leukemia, 82(6) BLOOD 1701–12 (1993) ("Waldman '93")	
1537	Hakimi et al., Reduced Immunogenicity and Improved Pharmacokinetics of Humanized ANTI-Tac in Cynomolgus Monkeys, 147(4) J. IMMUNOLOGY 1352–59 (1991) ("Hakimi '91")	
1538	Vincenti et al., Interleukin 2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation, 338(3) NEW ENG. J. MED. 161–65 (1998) ("Vincenti '98")	
1539	SEER Stat Fact Sheets: Breast Cancer, National Cancer Institute, http://seer.cancer.gov/statfacts/html/breast.html (last accessed March 17, 2017)	
1540	Harris <i>et al.</i> , <i>Medical Progress: Breast Cancer</i> , 327(5) NEW ENG. J. MED. 319–28 (1992) ("Harris '92")	

PETITIONER'S EXHIBIT LIST		
Exhibit No.	Description	
1541	King et al., Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma, 229(4717) SCIENCE 974–76 (1985) ("King '85")	
1542	Semba et al., A v-erbB-Related Protooncogene, c-erbB-2, is Distinct from the c-erbB-1 / Epidermal Growth Factor-Receptor Gene and is Amplified in a Human Salivary Gland Adenocarcinoma, 82(19) PROC. NAT'L ACAD. SCI. USA 6497–01 (1985) ("Semba '85")	
1543	Coussens et al., Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene, 230(4730) SCIENCE 1132–39 (1985) ("Coussens '85")	
1544	Fukushige et al., Localization of a Novel v-erbB-Related Gene, c- erbB-2, on Human Chromosome 17 and its Amplification in a Gastric Cancer Cell Line, 6(3) MOLECULAR CELLULAR BIOLOGY 955–58 (1986)	
1545	Slamon et al., Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene, 235(4785) SCIENCE 177–82 (1987) ("Slamon '87")	
1546	Kraus et al., Overexpression of the EGF Receptor-Related Proto- Oncogene erbB-2 in Human Mammary Tumor Cell Lines by Different Molecular Mechanisms, 6(3) The EMBO J. 605–10 (1987)	
1547	Hudziak et al., Increased Expression of the Putative Growth Factor Receptor p185 ^{HER2} Causes Transformation and Tumorigenesis of NIH 3T3 Cells., 84(20) PROC. NAT'L ACAD. SCI. USA 7159–163 (1987) ("Hudziak '87")	
1548	Shepard <i>et al.</i> , <i>Monoclonal Antibody Therapy of Human Cancer:</i> <i>Taking the HER2 Protooncogene to the Clinic</i> , 11(3) J. CLINICAL IMMUNOLOGY, 117–27 (1991)	
1549	Chothia et al., Conformations of Immunoglobulin Hypervariable Regions, 342(21) NATURE 877–83 (1989) ("Chothia '89")	

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.